Recent advancements in cellular reprogramming, including significant funding and clinical trials, are transforming anti-aging science by targeting root causes of age-related diseases. Cellular reprogr...
A new AI system, DeepRare, demonstrates superior accuracy in diagnosing rare diseases using real-time data and self-reflective reasoning, as detailed in a 2026 Nature study, with potential to reduce d...
Advanced coronary CT scans with machine learning now quantify plaque volume more accurately than LDL levels, enabling early intervention and personalized prevention for cardiovascular disease. New AI-...
Life Biosciences receives FDA clearance for the first human trial of cellular reprogramming targeting glaucoma and NAION, signaling regulatory openness to longevity therapies and potential vision rest...
Stanford Medicine study finds inhibiting 15-PGDH enzyme regenerates cartilage in aged mice, offering a non-invasive osteoarthritis treatment that could reduce joint replacements and improve life quali...
Recent advances in mRNA technology for cancer vaccines show promise with improved stability, targeted delivery, and AI-driven antigen design, transforming immunotherapy approaches. Cutting-edge mRNA v...
This article analyzes the critical role of AI product owners in healthcare, focusing on FDA regulations, real-world case studies, and the balance between innovation and patient safety for improved out...
Analysis of initiatives like RADIANT-CERSI that help startups navigate SaMD and AIaMD regulations, reducing costs and speeding market entry with real case studies. Programs like RADIANT-CERSI provide ...
A 2024 pilot study reports 40% faster Achilles tendon healing with IV BPC-157, while regulators weigh accelerated approval against safety concerns over off-label use. New clinical data on intravenous ...
New research shows herbal cubosomes enhance arthritis drug delivery while reducing side effects, with FDA fast-tracking two therapies and market projections reaching $1.2B by 2027. Breakthrough cuboso...
